Patients presenting with both HIV and cancer face a complex therapeutic challenge. The interplay between these two diseases can lead to unique clinical manifestations and present significant barriers in achieving optimal outcomes. Pharmacological interactions offer a promising approach for improving the treatment of this vulnerable patient segment